Clinical Trial Update: Determination of Assay Cut-Off for the RadTox Test in Prostate Cancer Patients to Predict GI Radiation Toxicity

View source ↗

Summary

A clinical trial evaluating the assay cut-off for the RadTox diagnostic test to predict GI radiation toxicity in prostate cancer patients has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• RadTox Test

Snippet

Sponsor: DiaCarta, Inc. | Conditions: Prostate Cancer | Status: WITHDRAWN